SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.

   Biotech / MedicalTrega Biosciences (TRGA), formerly HPIP


Previous 10 Next 10 
To: E.J. Neitz Jr who wrote ()6/21/2000 3:05:00 PM
From: bob zagorin
   of 152
 
i think i'm the only one alive on this thread but i've been buying more TRGA while is percolates in the low 3's on low volume. i like their business model; i think that all this stock needs is some volume and will fly.

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who wrote ()6/22/2000 11:49:00 PM
From: bob zagorin
   of 152
 
freeedgar.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject7/11/2000 11:41:55 AM
From: bob zagorin
   of 152
 
can't vouch for the source but here's an interesting write up.

Stockprowler's pick this week is…

Trega Biosciences, Inc. (TRGA:Nasdaq)

Corporate Web site: trega.com
Shares Outstanding: 23.3 million
Public Float: 11.2 million
Insider Ownership: 52%
Institutional Ownership: (20) 14%
Market Capitalization: $90.2 million
Closing Price Friday: $3.87
San Diego based Trega Biosciences, Inc. is focused on accelerating drug discovery from disease targets to clinical candidates through its iDiscovery™ technologies. Such technologies include the IDEA™("In Vitro Determination for the Estimation of ADME (absorption, distribution, metabolism and excretion)") computerized predictive models for, among other things, the prediction and selection of compounds with essential drug-like characteristics for further development and Chem.Folio™- combinatorial libraries for screening and optimization of potential drug candidates.

Since its inception, Trega has utilized combinatorial chemistry as a foundation for its drug discovery activities. This technology has enabled Trega to develop and offer a wide range of small-molecule libraries, including its Chem.Folio™ compound libraries. In 1993, Trega used its combinatorial chemistry technologies to discover a family of proprietary compounds that appear to influence the production and activity of certain cytokines through interaction with melanocortin receptors. These compounds include HP-228, which has competed a Phase II clinical trial in the treatment of post-operative pain in hip and knee replacements. As part of its activities, the Company formed collaborative partnerships in the area of drug discovery and development. Coinciding with this focus, Trega entered into collaborations with certain pharmaceutical companies to develop compounds active against certain melanocortin receptors.

The continuing development of Trega's combinatorial chemistry libraries led to the development of information relevant to the drug discovery process, which information was regularly supplied to library purchasers. The development of this information and a growing belief in the importance of information in the drug discovery process caused the Company to investigate opportunities to acquire technologies directed at creating information germane to the drug discovery process. In 1998, Trega acquired its wholly owned subsidiary, NaviCyte, Inc., whose business included the development of products and services to facilitate the rapid screening of compounds for pharmacokinetic characteristics through the use of computer models. With the technology acquired from NaviCyte, Trega developed and released the first of the IDEA™ predictive models. The initial model predicts human absorption of drugs, nutrients, and other chemicals. Subsequent versions are being developed to predict metabolic and toxicological performance. In addition the company has combined its Chem.Folio™ libraries and IDEA™ predictive models in a collection of technologies called iDiscovery™.

On February 11, 2000, the Company announced that it did not intend to continue to support internal drug discovery programs, including its melanocortin receptor programs, that are not funded by a collaborator. Trega believes this strategic shift will permit it to better focus its efforts and resources on the continuing development and commercialization of its iDiscovery-TM- technologies. Trega is currently carrying out a collaborative program in the area of diabetes, obesity and syndrome X, which is funded by Novartis Pharma AG.

The first stage of the drug discovery process is the identification of a biological target ("target"), typically a receptor that is responsible for causing a medical condition. The second stage in early discovery is the synthesis of compounds to be screened against the desired target, followed by high throughput screening. The screening process involves the testing of hundreds of thousands of compounds to identify potentially hundreds of compounds that demonstrate activity against the target of choice. Active compounds resulting from this process are known as "hits". The hits are then chemically modified in a series of sequential steps to identify compounds that (1) have improved activity at the target, (2) are absorbed following oral administration, (3) have appropriate metabolism characteristics and (4) do not have toxic effects. This series of steps results in the identification of drug candidates. The testing used to develop the candidate is called "lead optimization," and may involve animal models, which are low throughput and poorly predictive of ultimate success. A drug candidate then undergoes preclinical development and three phases of human clinical development before being filed for approval with the FDA.

The overall process is one of attrition with a high failure rate. The early stages of the process are highly automated. Genomics is identifying many new targets at a rapid rate. Combinatorial chemistry enables the production of hundreds of thousands of compounds, while high throughput screening enables the screening of these compounds. This highly automated process, however, feeds thousands of hits into lead optimization, a low throughput, animal model dependent process, which creates a bottleneck. In addition, the traditional drug discovery process is expensive. The average direct and indirect cost of bringing a new drug to market has been estimated to total approximately $650 million. It has been estimated that over 50% of all pharmaceutical products that reach human clinical trials fail as a result of inappropriate absorption, distribution, metabolism, excretion, or toxicity that was not predicted earlier in the drug development process. Approximately $400 million of the cost of an average new drug has been estimated to represent the cost of failed drugs.

The availability of potentially millions of compounds for screening and related data combined with the sequential and time-consuming nature of traditional drug discovery methods have increased the demand for products and services which can accelerate the overall drug discovery and development process. Trega's iDiscovery-TM- technologies include its information-based products that it believes will improve the probability of success and accelerate the pharmaceutical discovery and development process. The underlying premise of iDiscovery™ technologies is to increase the likelihood of clinical success by identifying those compounds with essential drug-like characteristics at an early stage in the development process.

Trega's recent presentations at the biotech conferences in Boston and San Diego were both informative and impressive...replays may be heard here. In addition, a replay of the Trega Biosciences annual shareholders meeting is available here.

In April, Trega completed a private placement secondary offering of 3.7 newly issued shares of common stock for gross proceeds to the company of approximately $11 million dollars. Trega anticipates that the proceeds of the offering will be used to fund product development, and to acquire additional products or capabilities. On June 2, 2000 analyst coverage on Trega Biosciences was initiated by First Security Van Kasper with a Buy rating and a 12 month target of $5. Stockprowler.com believes that Trega has innovative products in a hot sector… combine that with strong alliances and solid management and you have a company that is well poised for rapid growth. TRGA closed Friday at 3 7/8 up 22% on the week. Our 12 month target on TRGA is $5 - $7… which may very well prove conservative as Wall Street discovers what this little biotech is all about.

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject7/25/2000 8:35:48 AM
From: bob zagorin
   of 152
 
Trega Biosciences' IDEA(TM) Predictive Model Licensed by Roche Following Successful Validation Study

SAN DIEGO, July 25 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA), a company focused on commercializing technologies and products for accelerating drug discovery and development, today announced that following a successful validation study of its IDEA(TM) predictive model for drug absorption, F. Hoffmann-LaRoche Ltd., Basel, Switzerland, has taken an initial license to the software product for use in its drug discovery activities. Financial terms of the license were not disclosed.

The blinded study conducted by Trega encompassed a diverse set of eight drug compounds from different therapeutic classes and had a wide range of physical and chemical properties. Roche selected and supplied the compounds to Trega and specified the criteria that constituted an effective level of prediction. Using its IDEA(TM) model, Trega predicted the human absorption of all eight compounds within the specified criteria for success. The in silico predictions with the IDEA(TM) model were achieved within days for each compound, in contrast to the weeks and months which are traditionally needed to test absorption of compounds in in vivo models.

"Trega is pleased with the outcome of this external validation study," said Michael G. Grey, president and chief executive officer. "Our product development strategy has been to work closely with the research and development teams of large pharmaceutical companies, so that the IDEA(TM) models will fit their needs and procedures in every way. By working with Roche on this validation study, we were able to address their specific criteria as well as gain a true, blinded external validation of the predictive capability of this model. We are looking forward to continued input from Roche scientists in the coming months as they begin to apply the model to their drug discovery programs."

Mr. Grey added, "One of the most challenging steps in drug discovery has always been to determine from a myriad of potential drug candidates those which would be best absorbed in the body, and thus which candidates should be selected for clinical development. Currently, gaining the answer to that question is a time-consuming and inefficient series of sequential steps frequently conducted in animals. With the IDEA(TM) predictive model, we believe that we can add speed and parallel processing, without losing accuracy and thereby accelerate the lead optimization process."

The IDEA(TM) predictive model, an acronym for In Vitro Determination for the Estimation of ADME (absorption, distribution, metabolism and excretion), was developed by Trega with a consortium of prominent pharmaceutical companies. The absorption model was constructed to simulate the physiological process of drug absorption, and incorporates human physiological parameters. The model is trained with a proprietary database of in vitro and human in vivo pharmacokinetic data for selected drugs and drug candidates, including many that failed in the development process. This training set of compounds is unique in that it represents a very diverse set of drug properties. Trega plans to introduce a metabolism model at the end of this year and subsequently develop additional models that will enable the complete prediction of bioavailability. Trega plans to also extend its technology to predict toxicity.

Trega Biosciences, Inc. (Nasdaq: TRGA) is a premier provider of products that accelerate and improve drug discovery through its iDiscovery(TM) technologies linking biology and chemistry with information technologies. Trega's family of information-based models simulate, in silico, how drug candidates will be processed in the body, thereby enabling selection of those with optimal characteristics for clinical development. Together with its IDEA(TM) products, Trega's ChemFolio(R) libraries of information-enhanced small molecules are designed to facilitate the identification and optimization of drug candidates. For additional information on Trega, please visit our Web site at trega.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including whether these transactions will be successful, any additional licenses, alliances or other transactions will be agreed to, formed or expanded, whether any such transactions will be successful, the impact of competitive products and pricing, and other risks detailed from time to time in Trega's Securities and Exchange Commission filings. These forward-looking statements represent Trega's judgment as of the date of this release. Trega disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Trega Biosciences, Inc.

CO: Trega Biosciences, Inc.; F. Hoffmann-LaRoche Ltd.

ST: California

IN: MTC BIO

SU:

07/25/2000 08:05 EDT prnewswire.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject8/3/2000 6:58:22 PM
From: bob zagorin
   of 152
 
Trega Biosciences Reports Second Quarter 2000 Results

SAN DIEGO, Aug. 3 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA),
focused on commercializing technologies and products for accelerating drug
discovery and development, today reported that revenues for its second quarter
ending June 30, 2000 were $2.0 million, compared to $2.6 million for the same
period last year. The net loss for the second quarter was $3.1 million, or
$0.14 per share, compared with a net loss of $3.5 million, or $0.19 per share,
for the comparable period in 1999. Trega ended the quarter with approximately
$9.7 million in cash, cash equivalents and short-term investments.

Revenues for the six months ended June 30, 2000 were $4.6 million,
compared to $4.8 million for the same period last year. Among the revenues
for the first six months of 1999 was $1.1 million recognized for funded drug
discovery activities completed during the period. On February 11, 2000, the
company announced its intention to shift its focus to the development and
commercialization of its iDiscovery(TM) technologies and away from drug
discovery activities. The net loss for the six months was $7.4 million, or
$0.35 per share, compared to $6.2 million, or $0.34 per share for the six
months ended June 30, 1999.

"We were pleased to recently announce that following a successful
validation study of our IDEA(TM) predictive model for drug absorption, F.
Hoffmann-LaRoche Ltd. took an initial license to the model for use in its drug
discovery efforts. The results of the study represents a validation of the
ability of our absorption model to efficiently and accurately predict how drug
compounds are absorbed in the body. We will continue to pursue additional
pharmaceutical relationships," said Michael G. Grey, Trega's president and
chief executive officer. "As an increasing number of targets and compounds
become available, researchers will need to find ways to more rapidly and
accurately select the best drug candidates for development. Trega's
iDiscovery(TM) technologies, consisting of IDEA(TM) predictive models and
Chem.Folio(R) libraries, are designed to enable researchers to accelerate this
process."

Mr. Grey continued, "During the second quarter we developed a prototype of
a predictive model for metabolism and in the coming months we plan to carry
out the necessary development work to enable the release of a commercial
version of this important model. This will represent a significant step
towards achieving our goal of an integrated model designed to predict
bioavailability in humans."

Management also noted that it entered into an additional agreement in the
second quarter with Boehringer Ingelheim International GmbH using Trega's
Chem.Folio(R) program for the custom synthesis of exclusive compound
libraries.

Trega Biosciences, Inc. is a premier provider of products that accelerate
and improve drug discovery through its iDiscovery(TM) technologies linking
biology and chemistry with information technologies. Trega's IDEA(TM) family
of information-based models simulate, in silico, how drug candidates will be
processed in the body, thereby enabling selection of those with optimal
characteristics for clinical development. Together with its IDEA(TM)
products, Trega's ChemFolio(R) libraries of information-enhanced small
molecules are designed to facilitate the identification and optimization of
drug candidates. For additional information on Trega, please visit our Web
site at trega.com.

Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties. The Company's quarterly and annual financial
performance may be subject to fluctuations depending on factors such as the
receipt and timing of revenue recognized from sales, licenses and
collaborations, timing of the delivery of products and technologies, the
completion of contracted service commitments to Trega's customers and
partners, and potential future acquisitions or disposition of complementary
assets or technologies. Accordingly, revenue and operating results for prior
periods may not be indicative of Trega's future financial results. Other
forward-looking statements could include whether the Company's resources are
sufficient to enable it to reach its business objectives, whether any research
or development activities to be conducted as described will be successful,
whether any additional collaborations or alliances will be formed or expanded,
whether any such products can be successfully marketed, the impact of
competitive products and pricing in marketing success, whether any other
corporate collaborations or alliances will be successful, and other risks
detailed from time to time in Trega's Securities and Exchange Commission
filings. These forward-looking statements represent Trega's judgment as of
the date of this release. Actual results may differ materially from those
projected. Trega disclaims, however, any intent or obligation to update these
forward-looking statements.

TREGA BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations


(Unaudited)


(in thousands, except per share data)

Three Months Ended Six Months Ended


June 30, June 30,


2000 1999 2000 1999

Revenues:


Compound revenues $861 $1,196 $2,310 $1,561


Contract research


and licenses fees 1,180 1,365 2,283 3,031


Net sales 6 84 44 189

Total revenues 2,047 2,645 4,637 4,781

Costs and expenses:


Cost of sales 72 99 107 158


Research and development 4,151 4,353 8,599 8,941


Selling, general


and administrative 2,131 1,709 4,297 3,505

Total costs and expenses 6,354 6,161 13,003 12,604

Loss from operations


before equity in


losses of affiliate $(4,307) $(3,516) $(8,366) $(7,823)

Equity in losses


of affiliate (154) -- (340) --

Loss from operations (4,461) (3,516) (8,706) (7,823)

Interest and other


income (expense), net 1,313 27 1,258 1,654

Net loss $(3,148) $(3,489) $(7,448) $(6,169)

Basic and diluted


net loss per share $(0.14) $(0.19) $(0.35) $(0.34)

Shares used in computing


basic and diluted


net loss per share 23,191 18,053 21,302 17,953

TREGA BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets


(in thousands)


June 30, December 31,


2000 1999


(unaudited)

Cash, cash equivalents and


short-term investments $9,718 $6,434


Accounts receivable and other current assets 2,612 2,541


Property and equipment, net 4,245 4,179


Other assets 8,864 9,507


Total assets $25,439 $22,661

Current liabilities $7,347 $8,155


Long-term liabilities 2,908 2,996


Stockholders' equity 15,184 11,510


Total liabilities and stockholders' equity $25,439 $22,661

SOURCE Trega Biosciences, Inc.

CO: Trega Biosciences, Inc.

ST: California

IN: BIO MTC

SU: ERN

08/03/2000 17:02 EDT prnewswire.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject8/7/2000 11:32:43 AM
From: bob zagorin
   of 152
 
!0K
freeedgar.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject8/7/2000 11:32:52 AM
From: bob zagorin
   of 152
 
10K
freeedgar.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject8/14/2000 5:49:55 PM
From: bob zagorin
   of 152
 
freeedgar.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject8/15/2000 9:39:08 AM
From: bob zagorin
   of 152
 
Trega Biosciences Launches Enhanced Version of Its iDEA(TM) Predictive Model for Drug Absorption

- New Model Enables Researchers to Streamline Drug Discovery Efforts -

SAN DIEGO, Aug. 15 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA), focused on commercializing technologies and products for accelerating drug discovery and development, today announced the launch of an enhanced version of its iDEA(TM) predictive model for drug absorption. A key feature of the new module is that it uses data from in vitro studies with Caco-2 cells to predict drug absorption in the body. Caco-2 is a cell line widely used within the pharmaceutical and biotechnology industry as a surrogate to measure intestinal drug transport. The use of the data derived from Caco-2 cells further simplifies the input required to generate prediction of human absorption, thereby helping researchers more efficiently select the best drug candidate for development.

"Although Caco-2 cells have been used widely within the industry to generate drug transport data, Trega's enhanced absorption model represents the first externally validated predictive model to effectively use this data to confidently predict drug absorption in humans," said George Grass, Pharm.D., Ph.D., Trega's chief technology officer. "The model has been tested and validated using the same external data set from the recently successful iDEA(TM) validation study conducted in conjunction with F. Hoffman-La Roche."

Michael Grey, Trega's president and CEO, stated, "We believe that this enhancement to our absorption model will enable broader use of the iDEA(TM) predictive model by the pharmaceutical and biotechnology industry. By decreasing the amount of data required to evaluate the absorption characteristics of a compound and by offering researchers a way to streamline discovery, more compounds can be examined earlier in the process. Trega's iDEA(TM) predictive model enables the evaluation of drug absorption in man both more rapidly and predictively than other currently used methods, which rely on extensive animal experimentation."

The iDEA(TM) predictive model, an acronym for In Vitro Determination for the Estimation of ADME (absorption, distribution, metabolism and excretion), was developed by Trega with a consortium of prominent pharmaceutical companies. The absorption model was constructed to simulate the physiological process of drug absorption, and incorporates human physiological parameters. The model is trained with a proprietary database of in vitro and human in vivo pharmacokinetic data for selected drugs and drug candidates, including many that failed in the development process. This training set of compounds is unique in that it represents a very diverse set of drug properties. Trega plans to introduce a metabolism model at the end of this year and subsequently intends to develop additional models that will enable the complete prediction of bioavailability.

Trega Biosciences, Inc. is a premier provider of products that accelerate and improve drug discovery through its iDiscovery(TM) technologies linking biology and chemistry with information technologies. Trega's iDEA(TM) family of information-based models simulate, in silico, how drug candidates will be processed in the body, thereby enabling selection of those with optimal characteristics for clinical development. Together with its iDEA(TM) products, Trega's ChemFolio(R) libraries of information-enhanced small molecules are designed to facilitate the identification and optimization of drug candidates. For additional information on Trega, please visit our Web site at trega.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including whether the Company's resources are sufficient to enable it to reach its objectives as described above, whether the iDEA(TM) software will be successfully completed, operated or commercialized, whether any research to be conducted as described will be successful, the impact of competitive products and pricing, in marketing success, whether any corporate collaborations or alliances will be formed or will be successful, and other risks detailed from time to time in Trega's Securities and Exchange Commission filings. These forward-looking statements represent Trega's judgment as of the date of this release. Actual results may differ materially from those projected. Trega disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Trega Biosciences, Inc.

CO: Trega Biosciences, Inc.

ST: California

IN: MTC BIO

SU:

08/15/2000 07:01 EDT prnewswire.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject8/30/2000 10:58:31 AM
From: bob zagorin
   of 152
 
Outsourcing of Early Discovery Chemistry Experiences to be Discussed By 7 Pharma Giants at Conference & Expo From October 25-27, Long Branch, NJ

LONG BRANCH, N.J., Aug. 30 /PRNewswire/ -- Early discovery chemistry outsourcing experiences will be discussed by the pharmaceutical giants Bristol-Myers Squibb, Pharmacia Corporation, SmithKline Beecham, Glaxo Wellcome, Pfizer Global Research, Ann Arbor Labs, and DuPont Crop Protection at "Outsourcing Discovery Chemistry & Chemical Development Services" in Long Branch, NJ, from October 25-27, announces Strategic Research Institute.

The meeting, the fourth in the series since July/99, will be broadly attended by the pharmaceutical, fine chemical, CRO, and biotech communities.

To register, please call 212.967.0095, x232; the fee is $1295.

To request additional information and/or book your hotel room, contact Anit Hora at ahora@srinstitute.com or 212-967-0095, x261. NO ROOM RESERVATIONS MAY BE MADE DIRECTLY BY CONTACTING THE HOTEL. Please include email and snail mail addresses to expedite your request.

The early discovery outsourcing talks are as follow:

-- Outsourcing Custom Synthesis Supporting Early Discovery

Mark Creswell, Pfizer Global Research, Ann Arbor Laboratories

-- Building a Collection of Novel, Non-Commercially Available Monomers by

Outsourced Custom Synthesis Duncan Judd, Glaxo Wellcome - UK

-- Technical Aspects of Outsourcing Combinatorial Chemistry

Mike Howard, DuPont Crop Protection

-- Procuring Compounds and Combinatorial Libraries from External Sources

Richard Thomas, Pharmacia Corporation

-- A Global Strategy to Develop a Primary Screening Deck

Michael Sofia, Bristol-Myers Squibb

-- Compound Acquisition: Where Have We Been & Where Do We Go Next?

David Langley, Glaxo Wellcome - UK

The early conference sponsor and exhibition list includes ChemFirst, Organix, Gateway Chemical, Array BioPharma, ArQule, MediChem Life Sciences, Camitro Corporation, Trega Bioscience, Engineered Tecnologies, Pharmacopeia, Peakdale Fine Chemicals, and CarboGen.

The full agenda is as follows:

-- Chemical Outsourcing Trends Panel Discussion: A View from The Street

Moderator, Stefan Loren, Legg Mason

-- Outsourcing Custom Synthesis Supporting Early Discovery

Mark Creswell, Pfizer Global Research, Ann Arbor Laboratories

-- Building a Collection of Novel, Non-Commercially Available Monomers by

Outsourced Custom Synthesis

Duncan Judd, Glaxo Wellcome - UK

-- Technical Aspects of Outsourcing Combinatorial Chemistry

Mike Howard, DuPont

-- The Novartis-Vertex Drug Discovery Collaboration

Roger Tung, Vertex Pharmaceuticals

-- The Pfizer - ArQule Drug Research & Technology Licensing Agreement

Sheila Dewitt, ArQule, Inc.

-- Outsourcing Natural Products Discovery: Biodiversity, Combinatorial

Biosynthesis and Libraries for Rapid Hit Prioritization & Lead

Identification, Steve Wrigley, Terragen, Inc. - UK

-- Procuring Compounds from and Combinatorial Libraries from External

Sources

Richard Thomas, Pharmacia Corporation

-- A Global Strategy to Develop a Primary Screening Deck

Mike Sofia, Bristol-Myers Squibb

-- External Compound Acquisition: Where Do We Go From Here?

David Langley, Glaxo Wellcome - UK

Panel on Intellectual Property

Moderated by Tom Saunders, Lorusso & Loud, Boston

-- Enhanced Innovation in Drug Discovery Through Chemical Outsourcing,

Kevin Koch, Array BioPharma

-- Outsourcing ADME/TOX/PK Assays

CEREP

-- The Whole Enchilada: Outsourcing of Proprietary Lead Discovery &

Optimization

Jonathan Burnbaum, Pharmacopeia

-- Outsourcing Chemistry to Pharma & Non-Pharma

Lew Makings, Aurora Biosciences

-- Outsourcing IT and Software Development to Accelerate Drug Discovery

Trevor Heritage, Tripos

-- Panel Discussion on Lead Discovery & Optimization

Moderated by Mike Howard, DuPont Crop Protection

Panelists: Oxford Asymmetry, Bristol-Myers Squibb, Hoffmann-La Roche,

Pfizer Global Research, Ann Arbor Laboratories, MediChem Life Sciences,

Glaxo Wellcome, Pharmacia Corporation

-- Implementing the Best Pharma - CRO Business Model

Moderator: John Budzinski, DuPont Pharmaceuticals

-- Case Study in Chemical Development Outsourcing

Abbott Laboratories

-- Outsourcing of Process Chemistry for Early Drug Candidates

Jolanta Nowakowski, Pfizer, Groton

-- Outsourcing of Bulk Actives: A Biotech Perspective

Jack Regan, Genentech

-- Panel on Outsourcing Chemical Development Services

Moderated by Michael Kolb, Wyeth Ayerst;

Panelists: Pfizer, Bristol-Myers Squibb, Merck & Company, Abbott Labs,

Schering Plough, Eli Lilly, Pharm-Eco Labs, Genentech

-- Outsourcing Process Research & Development at Eli Lilly

Thomas Eckrich, Eli Lilly & Company

QA Assurance and Chemical Development Outsourcing

Carl Rifino, AstraZeneca Pharmaceuticals

-- Small Company Outsourcing Manufacture of Final Product

Matt Hulbert, Cephalon

-- Chemical Outsourcing Regulatory (TBA)

SOURCE Strategic Research Institute

CO: Strategic Research Institute; Bristol-Myers Squibb; Pharmacia Corporation; SmithKline Beecham; Glaxo Wellcome; Pfizer Global Research; Ann Arbor Labs; DuPont Crop Protection

ST: New Jersey

IN: MTC

SU: TDS

08/30/2000 09:28 EDT prnewswire.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10